

## Shilpa Medicare Limited

## **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Date: 20 December 2024

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd. Exchange Plaza, 5<sup>th</sup> Floor, Plot No.C/1, G Block Bandra Kurla Complex, Bandra (E) **MUMBAI-400 051** 

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Reg, 2015.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

## Europe GMP Certificate for Shilpa Medicare Ltd. Unit VII, Nacharam, Hyderabad from EMA, Austria

This is to inform you that the Shilpa Medicare Limited, Unit 7, Nacharam, Hyderabad, Telangana, India had completed an inspection from EMA, Europe from 24<sup>th</sup> to 26<sup>th</sup> September 2024.

The Company has received the GMP Certification after successful closure of the inspection.

Shilpa Medicare Limited, Unit VII, has an Analytical Services Division (QC) and a Bio Analytical Department. Both laboratories are approved by USFDA. The Bio-Analytical Laboratory is already approved by EMA, Europe.

This inspection was the first Europe inspection for the QC laboratory of Unit VII. This Laboratory is involved in testing drug substances, raw materials, packing materials and finished products. It is also engaged in other analytical activities like analytical method validations, method transfers and other miscellaneous analytical studies. The laboratory has been testing samples for final release into US, EU and other markets.

## **About Shilpa:**

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

Thanking you,

For **SHILPA MEDICARE LIMITED** 

Ritu Tiwary
Company Secretary & Compliance Officer